GILD vs LIMN: Which Is the Better Buy in 2026?

Last updated November 2026

Short answer

GILD is the larger of the two ($210.05B market cap): the incumbent the market prices for continued execution (16.73x forward earnings, beta 0.37). LIMN is the smaller challenger ($3.83M): more room to run, but more to prove. The real question is which set of drivers you believe, and whether owning one (or both) leaves you over-concentrated.

GILD vs LIMN: the tie-breaker metrics

Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

MetricGILDLIMNWhat it tells you
Market cap$210.05B$3.83MSize. The larger name is the incumbent; the smaller has more room to grow and more to prove.
Beta0.370.78Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through.
Price vs 52-week range88% of range0% of rangeWhere today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why.
Price / book16.1210.61How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price.

Before you buy: how GILD and LIMN affect your concentration

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. GILD and LIMN share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined GILD and LIMN exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

What does Gilead Sciences (GILD) do?

Gilead Sciences is a large biopharmaceutical company best known for its leadership in treating viral diseases, especially HIV. Its HIV franchise, anchored by widely used single-tablet regimens like Biktarvy and the twice-yearly prevention injection Yeztugo (lenacapavir) for pre-exposure prophylaxis, generates the bulk of its revenue and is a global standard of care: HIV sales were about $5.7 billion in the second quarter of 2026, up 12% from a year earlier. Gilead also has a significant presence in liver diseases, including hepatitis B and C, where its cures transformed treatment, and in COVID-19 with the antiviral remdesivir (Veklury), now a shrinking contributor. Gilead has expanded into oncology through acquisitions, building a portfolio in cell therapy (CAR-T) and antibody-drug conjugates for cancers such as breast and bladder cancer, and in 2026 it added Arcellx, Tubulis and Ouro Medicines, plus an October 2026 partnership with Vir Biotechnology on T-cell engagers for solid tumors. The company makes money by selling these prescription medicines worldwide, supported by patents and strong pricing. Headquartered in Foster City, California, Gilead generated about $30.5 billion of revenue over the last twelve months, pays a dividend of $3.28 per share a year, and is investing to diversify into oncology and other areas as it manages future patent expirations.

Full GILD guide

What does Liminatus Pharma (LIMN) do?

Liminatus Pharma, Inc. is a clinical-stage immuno-oncology company based in Cerritos, California, focused on therapies that use the immune system to detect and attack cancer cells. Its lead candidate is IBA101, a humanized anti-CD47 monoclonal antibody intended as a next-generation immune checkpoint inhibitor, with an initial focus on advanced solid tumors including non-small cell lung cancer. The broader pipeline includes a Guanylyl Cyclase C (GCC) cancer vaccine program and, through its transaction with InnocsAI (governed by an amended definitive merger agreement), CAR-T and antibody candidates such as IBC101, a CD19xCD22 bivalent CAR-T for B-cell malignancies cleared for an early-phase study in Korea, plus a CS1 antibody platform. In August 2026 the company engaged Synex as contract research organization for the Phase 1/2a development of the CD19xCD22 CAR-T. The company has no approved products, generates no revenue, and Yahoo Finance lists a single employee.

Full LIMN guide

GILD vs LIMN: how do they differ?

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

  • GILD drivers: Dominant HIV franchise; Oncology expansion, now accelerated by deals.
  • LIMN drivers: Lead anti-CD47 program; Pipeline breadth and the InnocsAI deal.

Which fits which kind of investor

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: Gilead is heavily dependent on its HIV franchise, so any new competition, pricing pressure, or patent expiration there is a major risk. For LIMN, liminatus carries the full stack of risks that define a distressed pre-revenue biotech.

GILD or LIMN: which should you pick?

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick GILD if you believe its drivers more; LIMN if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the GILD and LIMN guides.

GILD vs LIMN: the full fundamentals

GILD. Gilead is valued as a mature, cash-generative biopharma at about 16 times forward earnings, above where it traded a year ago after a roughly 28% gain in 2026. Reported earnings are negative over the last twelve months because of about $11 billion of acquired research charges, so investors focus on product revenue (guided to $30.1-30.4 billion for 2026) and free cash flow. Third-quarter results are due October 29, 2026, with consensus near $2.20 of adjusted EPS on about $7.8 billion of revenue.

LIMN. For a clinical-stage biotech with no revenue, traditional metrics like P/E or price-to-sales do not apply, so the numbers that matter are cash on hand, the cash burn, and the runway between them. Here the runway is very short: a trailing net loss of about $12.5 million and operating cash outflow near $4 million against roughly $3 million in cash means the company must keep raising money to operate, which is why management disclosed going concern doubt. Read the roughly $4 million market cap as the market's small, heavily discounted estimate of a binary pipeline rather than a multiple of any earnings, and treat each financing and clinical update as the real value driver.

Headline figures (approximate, October 2026): GILD shows revenue (ttm) ~$30.5 billion, revenue growth (latest quarter, yoy) ~10%, operating margin ~34%, net income (ttm) ~-$3.2 billion (acquired IPR&D charges); LIMN shows revenue $0 (no approved products), net loss (ttm) ~$12.5 million, net loss (fy2025) ~$10.2 million, cash / debt ~$3.0 million / ~$1.4 million (Jun 30, 2026).

The bottom line: GILD vs LIMN

GILD and LIMN are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined GILD and LIMN exposure against your real portfolio. It is not an investment adviser.

Wondering how GILD or LIMN fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about Gilead Sciences

Ask Walnut's AI anything about GILD and see how it fits what you own.

FAQ

What is the difference between GILD and LIMN?

+

Gilead Sciences is a large biopharmaceutical company best known for its leadership in treating viral diseases, especially HIV. Liminatus Pharma, Inc. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.

Is GILD or LIMN the better stock?

+

Neither is universally better. GILD is the larger incumbent; LIMN is the smaller challenger. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.

Which is cheaper, GILD or LIMN?

+

A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.

Should you own both GILD and LIMN?

+

Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.

What are the risks of GILD vs LIMN?

+

GILD: Gilead is heavily dependent on its HIV franchise, so any new competition, pricing pressure, or patent expiration there is a major risk. Hepatitis C revenue declined sharply after its cures shrank the patient pool, illustrating how success can erode markets, and Veklury sales are fading (2026 guidance cut to about $300 million). Its oncology expansion has been costly and uneven: the 2026 acquisitions pushed reported results to a GAAP loss of about $10.5 billion in the second quarter and a trailing net loss of about $3.2 billion, and the Immunomedics impairment shows acquired programs can underperform. Debt stood near $26 billion against about $4.9 billion of cash at the end of June. Drug development is risky, with frequent trial failures. The company faces regulatory, reimbursement, and drug-pricing policy pressures, including in the US. After a strong 2026 run the stock trades near the average analyst target of about $160, leaving less room for disappointment. Diversifying away from virology successfully is essential but unproven at scale. LIMN: Liminatus carries the full stack of risks that define a distressed pre-revenue biotech. It has no products and no revenue, an accumulated deficit above $40 million, and management has disclosed substantial doubt about its ability to continue as a going concern, meaning it may be unable to fund operations without raising more capital on potentially harsh terms. Its lead asset, IBA101, is still early and unproven, and CD47 is a target where larger, better-funded programs have repeatedly failed, so a single clinical setback could be decisive given how concentrated the value is in a handful of early programs. The company regained Nasdaq bid-price compliance in September 2026 only through a 1-for-50 reverse split, and continued financings, plus the share issuance tied to the InnocsAI transaction, point to heavy dilution. The stock is a micro-cap worth about $4 million with low liquidity and extreme volatility: on a split-adjusted basis it is down about 90% year to date and about 95% over one year, with a 52-week range of roughly $3.01 to $141.50. A total loss is a realistic outcome.

Related comparisons

Browse all stock comparisons.

Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell GILD or LIMN; figures are approximate and dated (as of November 2026). Verify current data before investing.